PATENT APPLICATION DOCKET NO.: 0725.1059-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		^م	
Applic	cants: David M. Knipe, Travis J. Taylor, Elizabeth E. McNamee	JC971 U.S.P	
Contin	nuation Application of	10/01	
	Application No.: 09/127,227	10	
	Filed: July 31, 1998		
For:	Replication-Competent Virus Expressing A Detectable Fusion Protein		
	Date: 01/116/02 Express Mail Label No. £ £ 9305 9887945		
	INFORMATION DISCLOSURE STATEMENT		
Assist	ant Commissioner for Patents		
Washi	ington, D.C. 20231		
Sir:			
This I	nformation Disclosure Statement is submitted:		
[]	under 37 CFR 1.129(a), or (First Second submission after Final Rejection)		
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including CPA, or a Request for Continued Examination).		
[]	under 37 CFR 1.97(c) together with either:		
	[] a Statement under 37 CFR 1.97(e), as checked below, or		
	[] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)		
[]	under 37 CFR 1.97(d) together with:		
	[] a Statement under 37 CFR 1.97(e), as checked below, and		
	a \$180.00 fee under 37 CFR 1.17(p), or		

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)



Statement Under 37 CFR 1.97(e)

[]	any cor	nmunic.	formation contained in this Information Disclosure Statement was first cited in a tion from a foreign patent office in a counterpart foreign application not more this prior to the filing of this Information Disclosure Statement; or
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contains in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
<u>St</u>	atem	ent Unc	ler 37 <u>C</u>	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.		
[X]	Enclos	ed herev	vith is form PTO-1449:
		[]	Copies	of the cited references are enclosed.
		[X]	Applic	of cited references are enclosed except those entered in prior application, U.S. ation No. 09/127,227, to which priority under 35 U.S.C. 120 is claimed. The application contains copies of the cited references.
		[]	The lis	ted references were cited in the enclosed International Search Report in a part foreign application.
		[]	The "counder 3	oncise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:
			[]	the explanation provided on the attached sheet.
			[]	the explanation provided in the Specification.
			[]	submission of the enclosed International Search Report.
			[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
			[]	the enclosed English language abstract.

[]	Applic	ant requests that the following n	on-published pending applic	cations be considered:
Examiner's Initials				
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	_
	[]	A copy of each above-cited app	olication, including the curre	ent claims, is enclosed.
	[]	A copy of each above-cited apprehase entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [ent claims, is enclosed, except], to which priority under
The Ex	xamine nces we	r is requested to return a copy of re considered with the next offic	the above list of pending ap e communication.	plications indicating which
It is re	quested	that the information disclosed h	nerein be made of record in t	his application.
Metho	d of pa	yment:		
[]	A cheaccom	eck for the fee noted above is enclosed, or the fee has been included in the check with the mpanying Reply. A copy of this Statement is enclosed.		
[]	Please	se charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is osed.		
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.
		I	Respectfully submitted,	
		I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		I	By Antowell Antoinette G. Giugliano	Leylaw

Registration No.: 42,582 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133 Dated: 11567

ATTORNEY DOCKET NO. APPLICATION NO. PTO 1449 REPRODUCED 0725.1059-001 INFORMATION DISCLOSURE CITATION APPLICANT IN AN APPLICATION David M. Knipe et al. January 15, 2002 FILING DATE GROUP January 16, 2002 U.S. PATENT DOCUMENTS SUB-FILING DATE EXAM NAME CLASS CLASS DATE INER DOCUMENT NUMBER APPROPRIATE INI-TIAL 22-AUG-89 Roizman 435 68 4,859,587 435 320.1 AB 5,288,641 22-FEB-94 Roizman 205.1 AC 12-JUL-94 424 5,328,688 Roizman 5 AD 5,658,724 19-AUG-97 DeLuca 435 435 5 ΑE 5,665,362 09-SEP-97 Inglis et al. AF AG FOREIGN PATENT DOCUMENTS TRANSLATION SUB-CLASS YES ИО DOCUMENT NUMBER DATE COUNTRY CLASS AL 28-JAN-88 EPO 0277773 ΜA 05-OCT-89 PCT WO89/09271 ΑN 16-APR-91 0453242 EPO AO WO92/05263 02-APR-92 PCT AΡ WO94/03207 17-FEB-94 PCT AQ WO94/21807 29-SEP-94 PCT AL2 WO94/03595 17-FEB-94 PCT AM2 20-JAN-94 PCT WO94/01573 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Shih, M.-F. et al., "Expression of hepatitis B virus S gene by herpes AR simplex virus type 1 vectors carrying $\alpha\text{-}$ and $\beta\text{-}\text{regulated}$ gene chimeras, " Proc. Natl. Acad. Sci. USA, 81:5867-5870 (1984). Nguyen, L.H. et al., "Replication-Defective Mutants of Herpes Simplex AS Virus (HSV) Induce Cellular Immunity and Protect against Lethal HSV Infection, " J. Virol., 66(12):7067-7072 (1992). Gao, M. and Knipe, D.M., "Genetic Evidence for Multiple Nuclear AT Functions of the Herpes Simplex Virus ICP8 DNA-Binding Protein, " J.Virol. 63(12):5258-5267 (1989). DATE CONSIDERED EXAMINER

PTO 1449 REPRO	DDUCED	ATTORNEY DOCKET NO. 0725.1059-001	APPLICATION NO.		
INFO	RMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David M. Knipe et al.			
	January 15, 2002	FILING DATE January 16, 2002	GROUP		
	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	t Pages, Etc.)		
AU	AU Cunningham, C. et al., "The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel. virus-induced protein kinase," J. Gen. Virol. 73:303-311 (1992).				
AV	Ali, M.A. et al., "Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2," Proc. Natl. Acad. Sci. USA, 88:8257-8261 (1991).				
AW	Rice, S.A. and Knipe, D.M., "Genetic Evidence for Two Distinct Transactivation Functions of the Herpes Simplex Virus α Protein ICP27, J. Virol., 64:1704-1715 (1990).				
AX	Rice, S.A. et al., "Herpes Simplex Virus Alpha Protein ICP27 Possesses Separable Positive and Negative Regulatory Activities," J. Virol., 63:3399-3407 (1989).				
AY	Quinn, J.P. and McGeoch, D.J., "DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein," Nucl. Acids Res., 13(22):8143-8163 (1985).				
AZ Sacks, W.R. et al., "Herpes Simplex Virus Type 1 ICP27 is an Essen Regulatory Protein," J. Virol. 55(3):796-805 (1985).					
AR2	Galloway, D.A. et al., "Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures, "Proc. Natl. Acad Sci. USA, 81:4736-4740 (1984).				
AS2	Weller, S.K. et al., "Genetic Analysis of Temperature-Sensitive Mutan Which Define the Gene for the Major Herpes Simplex Virus Type 1 DNA-Binding Protein," J. Virol., 45(1):354-366 (1983).				
AT2	Farrell, H. et al., "Vaccine potential of a herpes simples virus mutant lacking an essential glycoprotein," Abstract, 17th International Herpesvirus Workshop, Edinburgh, Scotland, Page 378 (August 1-7, 1992)				
AU2	McLean, L. et al., "Protective vaccination with a gH-deleted HSV-1 virus," 18th International Herpesvirus Workshop, Pittsburgh, PA, page C-71 (July 25-30, 1993).				
AV2					
AW2	Jayaraman, S. et al., "Exacerbation of Murine Herpes Simplex Virus-Mediated Stromal Keratitis by Th2 Type T Cells," J. Immunol., 151(10):5777-5789 (1993).				
AX2	Marchetti, M.E. et al., "A Temperature-Sensitive Mutation in a Herpes Simplex Virus Type 1 Gene Required for Viral DNA Synthesis Maps to Coordinates 0.609 through 0.614 in U ₁ ," J. Virol., 62(3):715-721 (1988)				
EXAMINER		DATE CONSIDERED			

			5hect 3 01 3		
PTO 1449 REPR	DDUCED	ATTORNEY DOCKET NO. 0725.1059-001	APPLICATION NO.		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT David M. Kline et al.			
January 15, 2002		FILING DATE January 16, 2002	GROUP		
	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinen	t Pages, Etc.)		
AY2	Ligas, M.W. and Johnson, D.C., "A Herpes Simplex Virus Mutant in which Glycoprotein D Sequences are Replaced by β -Galactosidase Sequences Binds to but is Unable to Penetrate into Cells," <i>J. Virol.</i> , $62(5):1486-1494$ (1988).				
AZ2	Farrell, H.E. et al., "Vaccine Potential of a Herpes Simplex Virus Type 1 Mutant with an Essential Glycoprotein Deleted," J. of Virol. 68(2):927-932 (1994).				
AR3	Morrison, L.A. and Knipe, D.M., "Immunization with Replication-Defective Mutants of Herpes Simplex Virus Type 1: Sites of Immune Intervention in Pathogenesis of Challenge Virus Infection," J. Virol. 68:689-696 (1994).				
AS3	Nguyen, L. et al., "Mechanism of Virus-Induced Ig subclass Shifts," J. Immunol. 152:478-484 (1994).				
AT3	Fields, B.N. <i>et al.</i> , "Field's Virology," Lippincot-Raven Publishers, Philadelphia, PA, Chapters 72 (1996).				
AU3	Sambrook, et al., "Molecular Cloning: A Laboratory Manual," 2nd ED., Chapter 17 (1989).				
AV3	Cruz, et al., PNAS, 93: 6286-6290 (1996).				
EWA	Gao, et al., Journal of Virology, 67: 876-885 (1993).				
AX3	Stauber, <i>et al.</i> , <i>Virology</i> , 213: 439-449 (1995).				
AY3	Phelan, et al., Nat. Biotechnol., 16(5): 440-443 (1998).				
AZ3	Loimas, et al., Biotechniques, 24(4): 614-618 (1998).				
AR4	Gerdes, et al., FEBS letters, 389: 44-47 (1996).				
AS4	Lee, et al., BBRC, 233: 288-292 (1997).				
AT4	Brideau, et al., Journal of Virology , 72(6): 4560-4570 (1998).				
AU4	Jons, et al., Journal of	Virological Methods, 66	5: 283-292 (1997).		
AV4	Desai, et al., Journal of Virology, 72(9): 7563-7578 (1998).				
EXAMINER	<u> </u>	DATE CONSIDERED			
1		1			